The cardiovascular effects of metoclopramide in multiple system atrophy and pure autonomic failure

Fabiola Magnifico, Giulia Pierangeli, Giorgio Barletta, Carmen Candela, Giuseppe Bonavina, Manuela Contin, Pietro Cortelli

Research output: Contribution to journalArticle

Abstract

Metoclopramide (MCP), a central and peripheral dopaminergic blocker with cholinergic activity, has been proposed to treat orthostatic hypotension (OH) on the basis that it could antagonize the vasodilator and natriuretic effects of dopamine. The authors evaluated cardiovascular responses to MCP in 11 subjects with OH: 6 with multiple system atrophy (MSA) and 5 with pure autonomic failure (PAF), along with 6 healthy control subjects. Supine blood pressure (BP), heart rate (HR), and breathing were continuously monitored before, during, and after MCP infusion. The pre-MCP head-up tilt test was tolerated at 65° for 10 minutes in all subjects except in one with PAF, who tolerated 30° for only 5 minutes. Tilting confirmed the OH in patients with MSA (change in mean arterial pressure [AMAP] = -31 ± 13 mm Hg) and PAF (ΔMAP = -34 ± 8 mm Hg). Infusion of MCP was given in four 5-mg doses every 5 minutes, with the subject in a supine position. Infusion of MCP induced the following effects: (1) A transient hypotensive effect occurred after each infusion in both patients and control subjects, the fall in MAP being counteracted by an increase in HR in control subjects but not in patients; this acute MAP fall was more severe in patients. (2) A progressive reduction of MAP occurred during the test, which never returned to preinfusion levels in patients; this effect was so pronounced in two PAF patients as to prevent them from receiving the last dose. Post-MCP tilting was tolerated in control subjects but in only in 5 MSA patients and 4 PAF patients. In those patients who tolerated the test, the MAP fall was similar to, or worse than, that before MCP (MSA: ΔMAP = -28 ± 16 mm Hg; PAF: ΔMAP = -38 ± 16 mm Hg). The cardiovascular effect of MCP in normal subjects was a transient hypotension counterbalanced by reflex tachycardia. The lack of an HR increase and the progressive fall in supine BP in MSA and PAF patients, together with worsening orthostatic tolerance after MCP infusion, are effects that should strongly discourage the use of this drug in the treatment of OH.

Original languageEnglish
Pages (from-to)163-168
Number of pages6
JournalClinical Autonomic Research
Volume11
Issue number3
Publication statusPublished - 2001

Fingerprint

Pure Autonomic Failure
Multiple System Atrophy
Metoclopramide
Orthostatic Hypotension
Heart Rate
Blood Pressure
Natriuretic Agents
Supine Position
Vasodilator Agents
Tachycardia
Hypotension
Cholinergic Agents
Reflex
Dopamine

Keywords

  • Autonomic failure
  • Metoclopramide
  • Multiple system atrophy
  • Orthostatic hypotension
  • Pure autonomic failure

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

The cardiovascular effects of metoclopramide in multiple system atrophy and pure autonomic failure. / Magnifico, Fabiola; Pierangeli, Giulia; Barletta, Giorgio; Candela, Carmen; Bonavina, Giuseppe; Contin, Manuela; Cortelli, Pietro.

In: Clinical Autonomic Research, Vol. 11, No. 3, 2001, p. 163-168.

Research output: Contribution to journalArticle

@article{e90d44d96ea04113bd8cd08d2c4227ca,
title = "The cardiovascular effects of metoclopramide in multiple system atrophy and pure autonomic failure",
abstract = "Metoclopramide (MCP), a central and peripheral dopaminergic blocker with cholinergic activity, has been proposed to treat orthostatic hypotension (OH) on the basis that it could antagonize the vasodilator and natriuretic effects of dopamine. The authors evaluated cardiovascular responses to MCP in 11 subjects with OH: 6 with multiple system atrophy (MSA) and 5 with pure autonomic failure (PAF), along with 6 healthy control subjects. Supine blood pressure (BP), heart rate (HR), and breathing were continuously monitored before, during, and after MCP infusion. The pre-MCP head-up tilt test was tolerated at 65° for 10 minutes in all subjects except in one with PAF, who tolerated 30° for only 5 minutes. Tilting confirmed the OH in patients with MSA (change in mean arterial pressure [AMAP] = -31 ± 13 mm Hg) and PAF (ΔMAP = -34 ± 8 mm Hg). Infusion of MCP was given in four 5-mg doses every 5 minutes, with the subject in a supine position. Infusion of MCP induced the following effects: (1) A transient hypotensive effect occurred after each infusion in both patients and control subjects, the fall in MAP being counteracted by an increase in HR in control subjects but not in patients; this acute MAP fall was more severe in patients. (2) A progressive reduction of MAP occurred during the test, which never returned to preinfusion levels in patients; this effect was so pronounced in two PAF patients as to prevent them from receiving the last dose. Post-MCP tilting was tolerated in control subjects but in only in 5 MSA patients and 4 PAF patients. In those patients who tolerated the test, the MAP fall was similar to, or worse than, that before MCP (MSA: ΔMAP = -28 ± 16 mm Hg; PAF: ΔMAP = -38 ± 16 mm Hg). The cardiovascular effect of MCP in normal subjects was a transient hypotension counterbalanced by reflex tachycardia. The lack of an HR increase and the progressive fall in supine BP in MSA and PAF patients, together with worsening orthostatic tolerance after MCP infusion, are effects that should strongly discourage the use of this drug in the treatment of OH.",
keywords = "Autonomic failure, Metoclopramide, Multiple system atrophy, Orthostatic hypotension, Pure autonomic failure",
author = "Fabiola Magnifico and Giulia Pierangeli and Giorgio Barletta and Carmen Candela and Giuseppe Bonavina and Manuela Contin and Pietro Cortelli",
year = "2001",
language = "English",
volume = "11",
pages = "163--168",
journal = "Clinical Autonomic Research",
issn = "0959-9851",
publisher = "D. Steinkopff-Verlag",
number = "3",

}

TY - JOUR

T1 - The cardiovascular effects of metoclopramide in multiple system atrophy and pure autonomic failure

AU - Magnifico, Fabiola

AU - Pierangeli, Giulia

AU - Barletta, Giorgio

AU - Candela, Carmen

AU - Bonavina, Giuseppe

AU - Contin, Manuela

AU - Cortelli, Pietro

PY - 2001

Y1 - 2001

N2 - Metoclopramide (MCP), a central and peripheral dopaminergic blocker with cholinergic activity, has been proposed to treat orthostatic hypotension (OH) on the basis that it could antagonize the vasodilator and natriuretic effects of dopamine. The authors evaluated cardiovascular responses to MCP in 11 subjects with OH: 6 with multiple system atrophy (MSA) and 5 with pure autonomic failure (PAF), along with 6 healthy control subjects. Supine blood pressure (BP), heart rate (HR), and breathing were continuously monitored before, during, and after MCP infusion. The pre-MCP head-up tilt test was tolerated at 65° for 10 minutes in all subjects except in one with PAF, who tolerated 30° for only 5 minutes. Tilting confirmed the OH in patients with MSA (change in mean arterial pressure [AMAP] = -31 ± 13 mm Hg) and PAF (ΔMAP = -34 ± 8 mm Hg). Infusion of MCP was given in four 5-mg doses every 5 minutes, with the subject in a supine position. Infusion of MCP induced the following effects: (1) A transient hypotensive effect occurred after each infusion in both patients and control subjects, the fall in MAP being counteracted by an increase in HR in control subjects but not in patients; this acute MAP fall was more severe in patients. (2) A progressive reduction of MAP occurred during the test, which never returned to preinfusion levels in patients; this effect was so pronounced in two PAF patients as to prevent them from receiving the last dose. Post-MCP tilting was tolerated in control subjects but in only in 5 MSA patients and 4 PAF patients. In those patients who tolerated the test, the MAP fall was similar to, or worse than, that before MCP (MSA: ΔMAP = -28 ± 16 mm Hg; PAF: ΔMAP = -38 ± 16 mm Hg). The cardiovascular effect of MCP in normal subjects was a transient hypotension counterbalanced by reflex tachycardia. The lack of an HR increase and the progressive fall in supine BP in MSA and PAF patients, together with worsening orthostatic tolerance after MCP infusion, are effects that should strongly discourage the use of this drug in the treatment of OH.

AB - Metoclopramide (MCP), a central and peripheral dopaminergic blocker with cholinergic activity, has been proposed to treat orthostatic hypotension (OH) on the basis that it could antagonize the vasodilator and natriuretic effects of dopamine. The authors evaluated cardiovascular responses to MCP in 11 subjects with OH: 6 with multiple system atrophy (MSA) and 5 with pure autonomic failure (PAF), along with 6 healthy control subjects. Supine blood pressure (BP), heart rate (HR), and breathing were continuously monitored before, during, and after MCP infusion. The pre-MCP head-up tilt test was tolerated at 65° for 10 minutes in all subjects except in one with PAF, who tolerated 30° for only 5 minutes. Tilting confirmed the OH in patients with MSA (change in mean arterial pressure [AMAP] = -31 ± 13 mm Hg) and PAF (ΔMAP = -34 ± 8 mm Hg). Infusion of MCP was given in four 5-mg doses every 5 minutes, with the subject in a supine position. Infusion of MCP induced the following effects: (1) A transient hypotensive effect occurred after each infusion in both patients and control subjects, the fall in MAP being counteracted by an increase in HR in control subjects but not in patients; this acute MAP fall was more severe in patients. (2) A progressive reduction of MAP occurred during the test, which never returned to preinfusion levels in patients; this effect was so pronounced in two PAF patients as to prevent them from receiving the last dose. Post-MCP tilting was tolerated in control subjects but in only in 5 MSA patients and 4 PAF patients. In those patients who tolerated the test, the MAP fall was similar to, or worse than, that before MCP (MSA: ΔMAP = -28 ± 16 mm Hg; PAF: ΔMAP = -38 ± 16 mm Hg). The cardiovascular effect of MCP in normal subjects was a transient hypotension counterbalanced by reflex tachycardia. The lack of an HR increase and the progressive fall in supine BP in MSA and PAF patients, together with worsening orthostatic tolerance after MCP infusion, are effects that should strongly discourage the use of this drug in the treatment of OH.

KW - Autonomic failure

KW - Metoclopramide

KW - Multiple system atrophy

KW - Orthostatic hypotension

KW - Pure autonomic failure

UR - http://www.scopus.com/inward/record.url?scp=0035736413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035736413&partnerID=8YFLogxK

M3 - Article

C2 - 11605821

AN - SCOPUS:0035736413

VL - 11

SP - 163

EP - 168

JO - Clinical Autonomic Research

JF - Clinical Autonomic Research

SN - 0959-9851

IS - 3

ER -